| 41.39 1.2 (2.99%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 50.41 |
1-year : | 58.88 |
| Resists | First : | 43.16 |
Second : | 50.41 |
| Pivot price | 40.56  |
|||
| Supports | First : | 39.58 |
Second : | 37.36 |
| MAs | MA(5) : | 40.24 |
MA(20) : | 40.46 |
| MA(100) : | 30.67 |
MA(250) : | 0 | |
| MACD | MACD : | 0.6 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 56.3 |
D(3) : | 47.3 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 43.29 | Low : | 6.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MAZE ] has closed below upper band by 33.5%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.82 - 42.02 | 42.02 - 42.2 |
| Low: | 39.44 - 39.66 | 39.66 - 39.86 |
| Close: | 41.04 - 41.4 | 41.4 - 41.72 |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Mon, 12 Jan 2026
What dividend safety score for Maze Therapeutics Inc. stock - Inflation Watch & Proven Capital Preservation Tips - moha.gov.vn
Fri, 09 Jan 2026
Maze Therapeutics (MAZE) Stock Analysis: Exploring a 21.52% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Thu, 08 Jan 2026
Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale - TipRanks
Mon, 05 Jan 2026
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Mon, 22 Dec 2025
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
Fri, 07 Nov 2025
Wedbush Maintains Maze Therapeutics (MAZE) Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 86.3 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 2,440 (K) |
| EPS | -2.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -52.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -107 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -16.17 |
| PEG Ratio | 0 |
| Price to Book value | 5.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|